Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 53.32B 7.9B 6.87B 6.39B 5.87B 11.1B 754B 11.26B 75.33B 29.59B 376B 29.69B 29.03B 1,244B P/E 2026 *
39.2x
P/E 2027 * 31.4x
Enterprise Value 48.27B 7.16B 6.22B 5.79B 5.32B 10.05B 683B 10.19B 68.19B 26.78B 340B 26.87B 26.28B 1,126B EV / Sales 2026 *
5.97x
EV / Sales 2027 * 5.04x
Free-Float
61.14%
Yield 2026 *
0.96%
Yield 2027 * 1.18%
Jul. 31 Asymchem Laboratories to Subscribe for Subsidiary's New Shares for 1.05 Billion Yuan; Shares Up 6% MT
Jul. 27 AsymBio, Subsidiary of Asymchem Group Kicks Off Construction of Fengxian R&D Building CI
Jul. 10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 175.98 Yuan From 132.37 Yuan, Keeps at Buy MT
Jul. 10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$131.48 From HK$115.43, Keeps at Buy MT
Jun. 11 Asymchem Laboratories Co., Ltd. Approves Final Profit Distribution Plan to Be Implemented (A Shares) for 2025, Payable on June 26, 2026 CI
May. 27 Asymbio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates CI
May. 20 Citigroup's long position in H shares of Asymchem Laboratories (Tianjin) decreases to 4.99% on May 14 from 5.66%, HKEX filing says RE
May. 15 Asymchem Laboratories Co., Ltd. Recommends Final Dividend for the Year Ended 31 December 2025, Payable on 24 July 2026 CI
May. 13 Citigroup's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 5.36% on May 7, HKEX says RE
May. 04 JPMorgan Chase's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 7.64% on Apr 28 from 8.18%, HKEX filing shows RE
Apr. 28 Asymchem Laboratories' Profit Falls 6.8% in Q1; Shares Rise 8% MT
Apr. 27 Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 27 Asymchem Laboratories (Tianjin) Q1 net profit down 6.8% Y/Y RE
Manager TitleAgeSince
Chief Executive Officer 70 1998-10-06
Chief Executive Officer 49 2022-01-18
President - -
Director TitleAgeSince
Director/Board Member 49 2011-07-17
Chairman 70 1998-10-06
Director/Board Member 65 2011-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 7.54B
-0.53%-3.12%+51.15%+150.58% 1,030B
+0.21%-1.13%+53.26%+46.92% 617B
-2.51%-2.33%+32.56%+66.35% 455B
+0.06%+1.17%+36.21%+31.25% 350B
-0.14%-0.83%+33.24%+40.28% 299B
-0.69%-0.44%+9.86%+14.23% 265B
-7.37%-4.31%-5.69%-41.99% 225B
-0.64%+3.68%+27.80%+62.95% 209B
-0.82%-0.50%+13.46%+69.41% 163B
Average -0.75%+4.83%+27.98%+48.89% 401.41B
Weighted average by Cap. -0.24%+4.87%+36.61%+70.85%

Financials

2026 *2027 *
Net sales 8.08B 1.2B 1.04B 969M 890M 1.68B 114B 1.71B 11.42B 4.48B 57B 4.5B 4.4B 189B 9.7B 1.44B 1.25B 1.16B 1.07B 2.02B 137B 2.05B 13.71B 5.38B 68.44B 5.4B 5.28B 226B
Net income 1.4B 208M 181M 168M 154M 292M 19.83B 296M 1.98B 778M 9.89B 781M 763M 32.72B 1.77B 262M 228M 212M 195M 368M 25B 373M 2.5B 981M 12.47B 984M 963M 41.26B
Net Debt -5.05B -749M -650M -605M -556M -1.05B -71.4B -1.07B -7.13B -2.8B -35.62B -2.81B -2.75B -118B -4.39B -651M -566M -526M -484M -914M -62.11B -928M -6.21B -2.44B -30.98B -2.45B -2.39B -102B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Date Price Change
Trader
Investor
Global
Quality
ESG MSCI
-